tirzepatide nash liver fat phase 3 Effect of versus insulin degludec on content and abdominal adipose Tirzepatide for Medical Weight Loss – GLP-2 (T) - Simon's Compounding

The FLOW Trial: First GLP-1 Receptor Agonist Kidney Outcomes Trial The FLOW trial (N=3,533) was the first dedicated kidney outcomes trial for any GLP-1 receptor agonist [2]

An Ally for Long-Term Immunity and Energy An optimal glutathione level is crucial for keeping the body young, resilient, and healthy

Storage after reconstitution requires refrigeration at 2-8 degrees Celsius

Clinical studies show typical results: 4% body weight loss after two months 6% reduction after three months 8% decrease after four months The long-term results look even better

However, if the results hold true, researchers say it could lead to a shift in the way that type 1 diabetes is treated